Looking Beyond BioNTech/Biotheus To Future Potential China Deals
Bispecifics/ADCs To Attract More Foreign Interest?
Bispecific antibody and antibody-drug conjugate in oncology will still be the popular targets for cross-border deals in 2025. (Shutterstock) 
